ANAVEX LIFE SCIENCES CORP
ANAVEX LIFE SCIENCES CORP
Share · US0327973006 · AVXL · A1411S (XNCM)
Overview Financial Indicators
7,93 USD
-5,71 % -0,48 USD
NASDAQ CAPITAL MARKET (XNAS) · Current prices and charts at MoneyPeak
13.06.2025 22:38

Current Prices from ANAVEX LIFE SCIENCES CORP

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
AVXL
USD
13.06.2025 22:38
7,93 USD
8,21 USD
-3,35 %
XLON: London
London
0HFR.L
USD
13.06.2025 18:20
8,08 USD
8,21 USD
-1,53 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 1,27 % -5,26 % -15,82 % -6,26 % 110,34 % 94,36 %

Company Profile for ANAVEX LIFE SCIENCES CORP Share

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Company Data

Name ANAVEX LIFE SCIENCES CORP
Company Anavex Life Sciences Corp.
Symbol AVXL
Website https://www.anavex.com
Primary Exchange XNCM NASDAQ CAPITAL MARKET
WKN A1411S
ISIN US0327973006
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Market Capitalization 780 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 51 West 52nd Street, 10019 New York
IPO Date 2018-01-29

Stock Splits

Date Split
07.10.2015 1:4

Ticker Symbols

Name Symbol
Frankfurt 12X1.F
London 0HFR.L
NASDAQ AVXL

More Shares

Investors who ANAVEX LIFE SCIENCES CORP hold also have the following shares in their portfolio:
AB Active ETFs, Inc. AB Ultra Short Income ETF
AB Active ETFs, Inc. AB Ultra Short Income ETF ETF
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
ELECTRONIC ARTS INC
ELECTRONIC ARTS INC Share
GEORG FISCHER NA  SF 1
GEORG FISCHER NA SF 1 Share
INTEL CORP
INTEL CORP Share
JPMORGAN CHASE & CO
JPMORGAN CHASE & CO Share
MICROSOFT CORP
MICROSOFT CORP Share
NXP SEMICONDUCTORS NV
NXP SEMICONDUCTORS NV Share
UNIEUROSTOXX 50  A
UNIEUROSTOXX 50 A Fund
UPWORK INC
UPWORK INC Share
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025